These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 16424034)

  • 1. Activity of the adenoviral E1A deletion mutant dl922-947 in ovarian cancer: comparison with E1A wild-type viruses, bioluminescence monitoring, and intraperitoneal delivery in icodextrin.
    Lockley M; Fernandez M; Wang Y; Li NF; Conroy S; Lemoine N; McNeish I
    Cancer Res; 2006 Jan; 66(2):989-98. PubMed ID: 16424034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantifying the activity of adenoviral E1A CR2 deletion mutants using renilla luciferase bioluminescence and 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography imaging.
    Leyton J; Lockley M; Aerts JL; Baird SK; Aboagye EO; Lemoine NR; McNeish IA
    Cancer Res; 2006 Sep; 66(18):9178-85. PubMed ID: 16982761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bevacizumab increases viral distribution in human anaplastic thyroid carcinoma xenografts and enhances the effects of E1A-defective adenovirus dl922-947.
    Libertini S; Iacuzzo I; Perruolo G; Scala S; Ieranò C; Franco R; Hallden G; Portella G
    Clin Cancer Res; 2008 Oct; 14(20):6505-14. PubMed ID: 18927290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p21 Promotes oncolytic adenoviral activity in ovarian cancer and is a potential biomarker.
    Flak MB; Connell CM; Chelala C; Archibald K; Salako MA; Pirlo KJ; Lockley M; Wheatley SP; Balkwill FR; McNeish IA
    Mol Cancer; 2010 Jul; 9():175. PubMed ID: 20598155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Icodextrin enhances survival in an intraperitoneal ovarian cancer murine model utilizing gene therapy.
    Rocconi RP; Numnum MT; Zhu ZB; Lu B; Wang M; Rivera AA; Stoff-Khalili M; Alvarez RD; Curiel DT; Makhija S
    Gynecol Oncol; 2006 Dec; 103(3):985-9. PubMed ID: 16857247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel ex vivo model system for evaluation of conditionally replicative adenoviruses therapeutic efficacy and toxicity.
    Kirby TO; Rivera A; Rein D; Wang M; Ulasov I; Breidenbach M; Kataram M; Contreras JL; Krumdieck C; Yamamoto M; Rots MG; Haisma HJ; Alvarez RD; Mahasreshti PJ; Curiel DT
    Clin Cancer Res; 2004 Dec; 10(24):8697-703. PubMed ID: 15623655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a formulation that enhances gene expression and efficacy following intraperitoneal administration in rabbits and mice.
    Engler H; Machemer TR; Schluep T; Wen SF; Quijano E; Wills KN; Harper AE; Maneval DC; Conroy SE
    Mol Ther; 2003 Apr; 7(4):558-64. PubMed ID: 12727120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of a replication-selective adenovirus against ovarian carcinomatosis is dependent on tumor burden, viral replication and p53 status.
    Heise C; Ganly I; Kim YT; Sampson-Johannes A; Brown R; Kirn D
    Gene Ther; 2000 Nov; 7(22):1925-9. PubMed ID: 11127580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adenovirus 5 E1a-mediated gene therapy for human ovarian cancer cells in vitro and in vivo.
    Zang RY; Shi DR; Lu HJ; Cai SM; Lu DR; Zhang YJ; Qin HL
    Int J Gynecol Cancer; 2001; 11(1):18-23. PubMed ID: 11285029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of oncolytic mutants targeting pRb and p53 pathways is synergistically enhanced when combined with cytotoxic drugs in prostate cancer cells and tumor xenografts.
    Radhakrishnan S; Miranda E; Ekblad M; Holford A; Pizarro MT; Lemoine NR; Halldén G
    Hum Gene Ther; 2010 Oct; 21(10):1311-25. PubMed ID: 20497039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological Inhibition of β3 Integrin Reduces the Inflammatory Toxicities Caused by Oncolytic Adenovirus without Compromising Anticancer Activity.
    Browne A; Tookman LA; Ingemarsdotter CK; Bouwman RD; Pirlo K; Wang Y; McNeish IA; Lockley M
    Cancer Res; 2015 Jul; 75(14):2811-21. PubMed ID: 25977332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncolytic adenoviral mutants induce a novel mode of programmed cell death in ovarian cancer.
    Baird SK; Aerts JL; Eddaoudi A; Lockley M; Lemoine NR; McNeish IA
    Oncogene; 2008 May; 27(22):3081-90. PubMed ID: 18071311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A fiber-modified, secretory leukoprotease inhibitor promoter-based conditionally replicating adenovirus for treatment of ovarian cancer.
    Rein DT; Breidenbach M; Kirby TO; Han T; Siegal GP; Bauerschmitz GJ; Wang M; Nettelbeck DM; Tsuruta Y; Yamamoto M; Dall P; Hemminki A; Curiel DT
    Clin Cancer Res; 2005 Feb; 11(3):1327-35. PubMed ID: 15709205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of the inflammatory cytokine TNF-α increases adenovirus activity in ovarian cancer via modulation of cIAP1/2 expression.
    Salako MA; Kulbe H; Ingemarsdotter CK; Pirlo KJ; Williams SL; Lockley M; Balkwill FR; McNeish IA
    Mol Ther; 2011 Mar; 19(3):490-9. PubMed ID: 21081903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-dose paclitaxel synergizes with oncolytic adenoviruses via mitotic slippage and apoptosis in ovarian cancer.
    Ingemarsdotter CK; Baird SK; Connell CM; Öberg D; Halldén G; McNeish IA
    Oncogene; 2010 Nov; 29(45):6051-63. PubMed ID: 20729921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paclitaxel resistance increases oncolytic adenovirus efficacy via upregulated CAR expression and dysfunctional cell cycle control.
    Ingemarsdotter CK; Tookman LA; Browne A; Pirlo K; Cutts R; Chelela C; Khurrum KF; Leung EY; Dowson S; Webber L; Khan I; Ennis D; Syed N; Crook TR; Brenton JD; Lockley M; McNeish IA
    Mol Oncol; 2015 Apr; 9(4):791-805. PubMed ID: 25560085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p53 selective and nonselective replication of an E1B-deleted adenovirus in hepatocellular carcinoma.
    Vollmer CM; Ribas A; Butterfield LH; Dissette VB; Andrews KJ; Eilber FC; Montejo LD; Chen AY; Hu B; Glaspy JA; McBride WH; Economou JS
    Cancer Res; 1999 Sep; 59(17):4369-74. PubMed ID: 10485485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A fiber-modified mesothelin promoter-based conditionally replicating adenovirus for treatment of ovarian cancer.
    Tsuruta Y; Pereboeva L; Breidenbach M; Rein DT; Wang M; Alvarez RD; Siegal GP; Dent P; Fisher PB; Curiel DT
    Clin Cancer Res; 2008 Jun; 14(11):3582-8. PubMed ID: 18519792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of autophagy enhances the effects of E1A-defective oncolytic adenovirus dl922-947 against glioma cells in vitro and in vivo.
    Botta G; Passaro C; Libertini S; Abagnale A; Barbato S; Maione AS; Hallden G; Beguinot F; Formisano P; Portella G
    Hum Gene Ther; 2012 Jun; 23(6):623-34. PubMed ID: 22475378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer.
    Vasey PA; Shulman LN; Campos S; Davis J; Gore M; Johnston S; Kirn DH; O'Neill V; Siddiqui N; Seiden MV; Kaye SB
    J Clin Oncol; 2002 Mar; 20(6):1562-9. PubMed ID: 11896105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.